2 Stocks to Buy Near Their 52-Week Lows

Pinterest reported Q3 revenue of roughly $1.0 billion (up 17% YoY) and EPS of $0.13 (vs $0.04 year-ago), with ARPU up 5% to $1.78, free cash flow rising 30% YoY to $318.4 million and MAUs at 600 million (+12% YoY); near-term weakness stems from disappointing guidance and tariff-related retail ad demand, though AI-driven search and ad improvements and Gen Z user growth support longer-term upside. Zoetis is seeing softer sales for newer OA drugs Librela and Solensia but retains strength in Apoquel and a large dermatology opportunity (est. >20M dogs untreated, 12M reached), a diversified portfolio (17 products >$100M, ~300 product lines) and a strong dividend track record (payouts up ~426% over the past decade), making it attractive for long-term investors despite near-term product headwinds.

Analysis

Market structure: Tariff-driven retail ad pullback directly pressures ad-dependent platforms (Pinterest PINS) and benefits ad-tech/AI vendors that can extract higher ARPU from stable MAUs; retailers and consumer discretionary names lose marketing ROI and may reallocate budgets to performance/search. Zoetis (ZTS) sits in a defensive pocket—veterinary services and established drug franchises gain pricing power as pet healthcare demand is inelastic and secularly growing, but recently launched OA drugs (Librela, Solensia) are short-term demand disappointments.

Risk assessment: Near term (days-weeks) equity reactions will track guidance and retail ad budgets; medium term (3–12 months) risks include tariff escalation, ad privacy regulation, or veterinary drug safety/patent issues; tail risks: a major regulatory recall for a Zoetis product or broad retail capex cuts reducing digital ad spend by >15% would materially hurt earnings. Hidden dependency: PINS monetization improvement depends on AI-driven relevance converting to advertiser ROI—if conversion lift <5–8% it won’t offset budget cuts.

Trade implications: Tactical longs in PINS as a mean-reversion/AI-monetization play and core longs in ZTS for dividend and defensive exposure are justified. Use option structures to size asymmetric exposure (buy LEAP calls on PINS, sell covered calls on ZTS) and a relative-value pair (long ZTS vs short small-cap pet-pharma/ELAN-style exposure) to isolate execution/launch risk. Entry triggers: add to PINS if price <15% from current 52-week low with ARPU growth ≥3% YoY; add to ZTS on >8% pullback or if Librela/Solensia q/q script growth >10%.

Contrarian angle: Consensus penalizes short-term launch and tariff noise while underweighting persistent fundamentals—600M MAUs and 5% ARPU growth for PINS with FCF +30% YoY is often mean-reverting into higher multiples once retail ad normalizes. For ZTS, the market may over-penalize early OA adoption curves; historical animal-health launches show multi-quarter adoption followed by durable revenue streams. Unintended consequence: crowded longs in PINS ahead of guidance could amplify downside on another weak quarter; size positions accordingly.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in PINS via 9–12 month LEAP calls (≈15–25% OTM) or shares if preferred; set tactical stop-loss at 15% below entry and a target of +35–50% within 12–18 months conditional on ARPU >3% YoY and MAUs ≥600M.
• Initiate a 3–4% core long in ZTS with buy-and-hold 12–36 months for dividend growth exposure; enhance yield by selling 1–2 month covered calls (10–20% OTM) and scale in an additional 1–2% if shares fall >8% or Librela/Solensia script volumes increase q/q by >10%.
• Construct a pair trade: long ZTS vs short ELAN (or similar small-cap pet-pharma) sized 1:1 for 2% net exposure over 6–12 months to capture durable franchise vs launch/cycle risk; exit if spread narrows by 50% or ZTS reports a regulatory/adverse event.
• Buy downside protection: allocate up to 0.5% of portfolio to a PINS 3–6 month put spread (cost-limited) to hedge guidance/tariff risk; liquidate if implied volatility contracts by >30% or after the next two earnings releases.
• Monitor triggers closely: reduce PINS exposure to zero if ARPU growth falls below 1% YoY or MAUs decline for two consecutive quarters; reduce ZTS exposure by 50% if Librela/Solensia combined prescriptions fail to grow >5% q/q over two quarters or if a formal regulatory safety signal emerges.